What are the treatment options for common electrolyte imbalances such as hyponatremia, hypernatremia, hypokalemia, hyperkalemia, hypocalcemia, and hypercalcemia?

Treatment of Electrolyte Imbalances

Hyponatremia

For severely symptomatic hyponatremia (seizures, coma, altered mental status, respiratory distress), immediately administer 3% hypertonic saline to correct 6 mmol/L over 6 hours, with a maximum correction of 8 mmol/L in 24 hours to prevent osmotic demyelination syndrome. 1

Acute Symptomatic Hyponatremia

• Patients with sodium <125 mEq/L and severe symptoms require emergency 3% hypertonic saline infusions 1, 2
• The critical threshold for seizure development is approximately 120 mmol/L 3
• Initial correction target: 6 mmol/L over the first 6 hours, then slow the rate 1
• Never exceed 8-10 mmol/L correction in 24 hours to avoid central pontine myelinolysis and osmotic demyelination syndrome 3, 1, 4
• Monitor sodium levels every 2 hours initially in severe cases, then every 4-6 hours after symptom resolution 1

Volume Status-Based Treatment

Hypovolemic Hyponatremia:

• Administer 0.9% normal saline for volume repletion at 15-20 ml/kg/hour during the first hour 1, 4
• Discontinue diuretics 1, 4
• Monitor sodium every 4-6 hours 1
• Avoid fluid restriction as it worsens the condition 4

Euvolemic Hyponatremia:

• First-line treatment is fluid restriction to 1 L/day 1
• Goal: increase sodium by 4-6 mmol/L per day 1
• Consider tolvaptan 15 mg once daily for persistent severe hyponatremia despite fluid restriction 1
• Evaluate and discontinue causative medications, particularly diuretics 4

Hypervolemic Hyponatremia:

• Fluid restriction to 1-1.5 L/day 1
• Temporarily stop diuretics if sodium <125 mmol/L 1
• Treat underlying condition (heart failure, cirrhosis) 2
• Consider albumin infusion in cirrhotic patients 1

Special Considerations for Neurosurgical Patients

• Hyponatremia ≤131 mmol/L merits evaluation and treatment 3
• Distinguish cerebral salt wasting (CSW) from SIADH by determining extracellular fluid volume status 3
• CSW requires sodium and intravenous fluid replacement 3
• In subarachnoid hemorrhage patients at risk for vasospasm: use fludrocortisone, avoid fluid restriction, and consider hydrocortisone to prevent natriuresis 3

---

Hypernatremia

Hypernatremia requires careful fluid replacement with hypotonic solutions, ensuring correction does not exceed 10 mmol/L per 24 hours to prevent cerebral edema. 4

Treatment Approach

• Administer isotonic saline (0.9% NaCl) initially for volume resuscitation if hypovolemic 4
• Transition to hypotonic fluid replacement for severe elevations 2
• Ensure induced change in serum osmolality does not exceed 3 mOsm/kg/h 4
• Monitor serum sodium, potassium, and renal function frequently during treatment 4
• Evaluate for diabetes insipidus, particularly in patients with intracranial pathology 5

---

Hyperkalemia

For life-threatening hyperkalemia, immediately stabilize the cardiac membrane with calcium gluconate or calcium chloride, shift potassium intracellularly with insulin/glucose and beta-agonists, then remove potassium using loop diuretics or newer potassium binders (patiromer or sodium zirconium cyclosilicate). 3, 6

Acute Life-Threatening Hyperkalemia

• Cardiac membrane stabilization: Calcium chloride or calcium gluconate IV 3, 6
• Hypertonic saline (3-5%) if concurrent hyponatremia 3
• Shift potassium intracellularly:
  • Insulin IV ± glucose 3, 6
  • Beta-2 adrenergic agonists (IV or nebulized salbutamol) 3, 6
  • Sodium bicarbonate if metabolic acidosis present 3, 6
• Remove potassium from body:
  • Loop diuretics (IV or oral) 3, 6
  • Hemodialysis for severe cases 3, 6
  • Potassium binders: patiromer, sodium zirconium cyclosilicate, or sodium polystyrene sulfonate 3, 6

Chronic Hyperkalemia Management in Hypertensive Patients

• For potassium 5.0-6.5 mEq/L: Continue RAAS inhibitors and initiate potassium-lowering agents (patiromer or sodium zirconium cyclosilicate) 6
• For potassium >6.5 mEq/L: Temporarily discontinue or reduce RAAS inhibitor and start potassium binders immediately 6
• Patiromer has slower onset but allows RAAS inhibitor continuation 6
• Sodium zirconium cyclosilicate has rapid onset, suitable for urgent outpatient scenarios 6
• Monitor potassium and renal function at 7-10 days after RAAS inhibitor initiation, then at 1-2 weeks, 3 months, and every 6 months 6

Antihypertensive Selection

• Preferred agents: calcium channel blockers, thiazide diuretics, loop diuretics 6
• Use beta-blockers and potassium-sparing diuretics with caution 6
• Continue RAAS inhibitors at optimal doses with concurrent potassium binder for long-term management 6

Critical Pitfall

• Insulin, salbutamol, and bicarbonate provide only temporary benefit (1-4 hours) without increasing potassium excretion; rebound hyperkalemia can occur after 2 hours, requiring early initiation of potassium-lowering agents 3

---

Hypokalemia

Hypokalemia is treated with potassium chloride supplementation, with careful monitoring to avoid overcorrection and cardiac complications. 3

Treatment Approach

• Administer potassium chloride (KCl) orally or intravenously 5
• Discontinue diuretics if they are the causative agent 4
• Monitor for neural paralysis, though emergencies occur relatively infrequently 5
• Address underlying causes: intestinal fluid losses, diuretic use 5

---

Hypercalcemia

Hypercalcemia requires immediate treatment with intravenous normal saline for volume expansion, followed by calcitonin or bisphosphonates for severe cases. 5

Treatment Approach

• Administer physiological saline solution for volume expansion 5
• Calcitonin for rapid effect 5
• Consider mithramycin (plicamycin) in malignancy-associated hypercalcemia 5
• Denosumab is an option for refractory cases 7
• Clinical symptoms include lassitude, tachycardia, nausea, vomiting, renal dysfunction, and neurological symptoms in severe cases 5

---

Hypocalcemia

Hypocalcemia with tetanic spasms requires immediate intravenous calcium administration, but only after assessing for alkalosis which can worsen symptoms. 5

Treatment Approach

• Intravenous calcium gluconate or calcium chloride for symptomatic patients 5
• Critical pitfall: During tetanic spasms, alkalosis may easily occur; obtain complete understanding of acid-base status before treatment 5
• Teriparatide may be considered in severe refractory cases 7
• Address underlying causes: renal insufficiency, vitamin D deficiency, hypothyroidism 5

---

General Monitoring Principles

• Electrolyte disorders are associated with increased morbidity and mortality in hospitalized patients 8, 9
• Multiple electrolyte imbalances occur in 18.8% of hospitalizations and carry significantly higher risk (OR 17.34 for adverse outcomes with ≥2 imbalances) 9
• Frequent monitoring is essential during correction of any electrolyte disorder 1, 4
• Treatment should not be delayed while pursuing definitive diagnosis in symptomatic patients 2